Mazen Darwazeh News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region

Hikma and Junshi Biosciences sign exclusive licensing agreement for cancer treatment drug toripalimab for the Middle East and North Africa region
quicknews-africa.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from quicknews-africa.net Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomJunshi bioscienceJunshi biosciencesMazen darwazehHikma pharmaceuticalsMiddle eastNorth africaSoutheast asiaExecutive vice chairman

Prince Hassan presides over launch of Jordanian-Japanese Friendship Association

AMMAN A ceremony announcing the establishment of the Jordanian-Japanese Friendship Association was held under the patronage of HRH Prince Hassan, on Wednesday. The event was attended by HRH Princess Sarvath Al Hassan, Princess Sumaya bint Al Hassan, Princess Wijdan Al Hashemi, Their Imperial Highnesses Princess Takamado and Princess Tsuguko of Japan, as well as Sasaki

Sasaki mikiyoAl hassanShefaa zghoulKing abdallahOkuyama jiroWijdan al hashemiKing abdullahMazen darwazehQueen raniaSarvath al hassanJapan international cooperation agencyJapanese friendship associationFriendship associationJordanian japanese friendship associationPrincess sumayaPrincess wijdan al hashemi

Hikma, Junshi Biosciences sign exclusive licencing agreement for cancer treatment drug toripalimab

AMMAN Hikma Pharmaceuticals, the multinational pharmaceutical company, on Monday announced a new exclusive licencing and commercialisation agreement with Junshi Biosciences, an innovation-driven biopharmaceutical company for toripalimab, in the Middle East and North Africa (MENA). Under the terms of the agreement, Hikma has an exclusive licence to develop and commercialise

Junshi biosciencesMazen darwazehHikma pharmaceuticalsMiddle eastNorth africaSoutheast asia

Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

SHANGHAI, China, Dec. 26, 2022 (GLOBE NEWSWIRE) Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated

United arab emiratesUnited statesUnited kingdomJunshi bioscienceJunshi biosciencesZhi liMazen darwazehIr teamDrug administrationRegulatory agencyNational reimbursement drug listEuropean medicines agencyPr teamHikma pharmaceuticalsShanghai junshi biosciences co ltdMiddle east

Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Hikma Sign Exclusive Licensing Agreement for Cancer Treatment Drug Toripalimab for the Middle East and North Africa Region

United arab emiratesUnited statesUnited kingdomSan franciscoJunshi bioscienceJunshi biosciencesZhi liMazen darwazehIr teamDrug administrationRegulatory agencyNational reimbursement drug listEuropean medicines agencyPr teamInstitute of microbiology the chinese academyHikma pharmaceuticals